Ambanelli U, Manganelli P, Ferraccioli G F
Z Rheumatol. 1982 Sep-Oct;41(5):235-9.
A follow-up of 15.4 months has been carried out in 50 patients suffering from classical or definite rheumatoid arthritis, treated with tiopronin, a new slow acting sulphydrylant agent. The attention was focused mainly on the frequency of the major side effects needing withdrawal of the drug in 20% of the patients; in other 20% of the cases we have observed the disappearance of the major side effects after reduction of the tiopronin dosage. The most important major side effect was renal toxicity. Five cases of proteinuria and among these four cases of nephrotic syndrome were recorded. These side effects disappeared 2-5 weeks after withdrawal of the tiopronin. From a clinical point of view a positive response was observed in 56% and a complete lack of efficacy in 22% of patients. The clinical benefit and a panel of side effects very close to those of D-penicillamine were confirmed.
对50例患有典型或确诊类风湿性关节炎的患者进行了为期15.4个月的随访，这些患者接受了一种新型慢效巯基药物硫普罗宁的治疗。主要关注的是20%的患者中需要停药的主要副作用的发生频率；在另外20%的病例中，我们观察到硫普罗宁剂量减少后主要副作用消失。最重要的主要副作用是肾毒性。记录了5例蛋白尿病例，其中4例为肾病综合征。这些副作用在停用硫普罗宁后2至5周消失。从临床角度来看，56%的患者观察到阳性反应，22%的患者完全无效。证实了其临床益处以及一组与青霉胺非常接近的副作用。
